Record EU award for UK biotech

2 August 2017

Politicians and bureaucrats in London and Brussels might be squabbling over the terms of Brexit, but the borderless nature of science and health imperatives are remaining resilient to such squabbles, a funding award shows.

Scottish start-up TC BioPharm has been selected for funding from the European Union's Horizon 2020 (H2020) research and innovation program. The biotech company has been awarded a 4 million euros ($4.7 million) H2020 grant to progress its innovative GDT (gamma-delta T) cell therapy for treatment of cancer.

"We share a single goal of improving cancer patient health and quality of life across EU borders"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK